Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last A$0.23 AUD
Change Today 0.00 / 0.00%
Volume 593.8K
PXS On Other Exchanges
Symbol
Exchange
OTC US
OTC US
Frankfurt
As of 2:10 AM 07/29/15 All times are local (Market data is delayed by at least 15 minutes).

pharmaxis ltd (PXS) Snapshot

Open
A$0.23
Previous Close
A$0.23
Day High
A$0.23
Day Low
A$0.23
52 Week High
05/18/15 - A$0.27
52 Week Low
10/30/14 - A$0.04
Market Cap
70.8M
Average Volume 10 Days
276.6K
EPS TTM
A$-0.12
Shares Outstanding
314.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PHARMAXIS LTD (PXS)

Related News

No related news articles were found.

pharmaxis ltd (PXS) Related Businessweek News

No Related Businessweek News Found

pharmaxis ltd (PXS) Details

Pharmaxis Ltd, a specialty pharmaceutical company, engages in the research, development, and commercialization of human healthcare products for the treatment and management of respiratory and other chronic diseases worldwide. The company’s lead product and product candidates are used for the diagnosis and treatment of chronic respiratory diseases, including asthma, cystic fibrosis, and chronic obstructive pulmonary disease (COPD), including bronchiectasis and chronic bronchitis, and other chronic and acute pulmonary conditions. It offers Aridol lung function test, which is designed to assist physicians in the assessment of asthma by identifying and measuring airway hyperresponsiveness; and Bronchitol, a drug designed to reduce the amount of mucus build-up in the lungs of patients suffering from chronic respiratory conditions. The company’s early product development pipeline includes orbital dry powder inhaler that delivers drug doses to the lungs; Lysyl Oxidase Like 2 (LOXL-2) inhibitors for the treatment of fibrosis; PXS64/25 targeting lung fibrosis; ASM8 targeting severe asthma; and PXS TPI1100 for the treatment candidate for COPD. Pharmaxis Ltd was founded in 1998 and is headquartered in Frenchs Forest, Australia.

83 Employees
Last Reported Date: 04/16/15
Founded in 1998

pharmaxis ltd (PXS) Top Compensated Officers

Chief Executive Officer, Director and Member ...
Total Annual Compensation: A$453.3K
Chief Financial Officer, Company Secretary an...
Total Annual Compensation: A$363.9K
Head of Drug Discovery
Total Annual Compensation: A$240.3K
Medical Director and Member of Disclosure Com...
Total Annual Compensation: A$348.4K
Compensation as of Fiscal Year 2014.

pharmaxis ltd (PXS) Key Developments

Boehringer Ingelheim Acquires PXS4728A from Pharmaxis

Boehringer Ingelheim GmbH has exercised its option and acquired the investigational drug PXS4728A from Pharmaxis Ltd. The drug PXS4728A will be used for the treatment of the liver-related condition nonalcoholic steatohepatitis (NASH) and to prevent its consequences. Under the terms of the transaction, Pharmaxis will receive an upfront payment of EUR 27.5 million and, subject to the continuing successful development and commercialization of the PXS4728A program, the following payments: up to a total of EUR 55 million in development milestone payments tied to the commencement of phase 2 and 3 clinical trials; up to a total of EUR 140 million in regulatory milestone payments upon filing of applications for marketing approval and receipt of regulatory and pricing approvals for a PXS4728A program product in the pharmaceutical market for the first indication; additional milestone payments similar in total to those set out above upon achievement of the same development and regulatory milestone events by a PXS4728A program product for a second indication; earn-out payments on annual net sales of PXS4728A program products at tiered percentages starting in the high single digits; and commercialization milestone payments upon achievement of specified levels of annual net sales of PXS4728A program products. Boehringer has also acquired other SSAO/VAP-1 inhibitor molecules related to PXS4728A and associated patents.

Pharmaxis Announces Completion of Restructuring and New Focus

Pharmaxis announced its transition to a strategic business plan with an increased focus on innovation and partnering in order to generate value. The new direction follows the completion of two years of restructuring that included partnering the Pharmaxis lead product Bronchitol in major markets worldwide, cutting the company's expense base and employee numbers and the sale of an early stage drug asset to Boehringer Ingelheim. The key elements of the Pharmaxis business plan announced are: New strategic direction ­ to build a regional biotech centre of excellence in fibrosis and inflammation. Multiple drugs from inhouse amine oxidase platform developed to phase 1 or 2. Collaborate where necessary to derisk and accelerate internal and external programs. Licence out to Big Pharma with attractive 1st in class drugs post phase 1 or 2. Short to midterm opportunities: Milestone payments from Boehringer as PXS4728A progresses. LOXL2 collaboration to phase 1 or 2 and subsequent partnering. 3 additional drug programs in the drug discovery pipeline. A stake in the US commercialisation of Bronchitol (funded by partner) and sales by distributors in the rest of the world. Financial strength: Restructured Bronchitol business to reduce investment (>50%) and shorten time to profitability. Pro forma March 31, 2015 balance sheet cash at $62 million.

Chiesi Farmaceutici S. p. A. Enters Distribution and Supply Agreement with Pharmaxis

Pharmaxis Ltd. has entered into an exclusive distribution and supply agreement with Chiesi Farmaceutici S. p. A. for the commercialisation of Bronchitol (mannitol) for cystic fibrosis in adults aged 18 years and above in Germany, the United Kingdom and Ireland. Under the terms of the agreement Chiesi will take over responsibility for the marketing, sales and distribution of Bronchitol from June 2015. The product was launched in Germany in 2012, in the United Kingdom in 2013 and is planned to be launched in Ireland after the current assessment for reimbursement is concluded. Germany and the United Kingdom account for more than 95% of current European sales.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PXS:AU A$0.23 AUD 0.00

PXS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PXS.
View Industry Companies
 

Industry Analysis

PXS

Industry Average

Valuation PXS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 9.6x
Price/Book 5.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 5.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PHARMAXIS LTD, please visit www.pharmaxis.com.au. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.